DOCSLIB.ORG

NSCLC (Update) • Cotellic + Zelboraf: Phase III 1L Melanoma (Cobrim), Overall Survival

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NSCLC (Update) • Cotellic + Zelboraf: Phase III 1L Melanoma (Cobrim), Overall Survival Roche YTD September 2015 sales Basel, 22 October 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group Severin Schwan Chief Executive Officer 4 Q3 2015: Guidance upgraded to mid-single digit sales growth1, Core EPS ahead of sales growth2 Growth YTD Sept Sales • Group sales +6%1 driven by HER2 franchise (+19%), Avastin (+9%), Actemra (+22%) and Professional Diagnostics (+7%) • Outperformance in all major regions: US (+6%1), Europe (+3%1), Japan (+6%1) and International (+8%1) Innovation Oncology • Atezolizumab: Phase II lung (POPLAR, BIRCH); Phase II bladder (IMvigor 210) • Alectinib: Phase II in 2L ALK+ NSCLC (update) • Cotellic + Zelboraf: Phase III 1L melanoma (coBRIM), overall survival Neuroscience • Ocrelizumab: – Phase III RMS (OPERA I/II) met primary and key secondary endpoints – Phase III PPMS (ORATORIO) met primary and key secondary endpoints Diagnostics • Launch of cobas EGFR Mutation Test v2 - first Roche liquid biopsy PCR test 1 At constant exchange rates (CER) 5 2 Excluding sale of filgrastim rights in 2014 YTD Sept 2015: Strong sales growth continues 2015 2014 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 27.7 27.0 3 6 Diagnostics Division 7.8 7.8 1 6 Roche Group 35.5 34.8 2 6 CER=constant exchange rates 6 Q3 2015: Sales growth for fifth consecutive year 10% 8% 8% 7% 7% 6% 6% 6% 6% 6% 6% 5% 5% 4% 5% 4% 4% 4% 4% 2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 All growth rates at constant exchange rates (CER) 7 YTD Sept 2015: Strong sales growth in all regions CHFbn 18 +6% 15 +1% 12 +3% +8% 9 Diagnostics +2% +14% +7% Pharma 6 +6% -5% +3% 3 +6% +8% 0 Japan International Europe US All growth rates at constant exchange rates (CER) 8 Roche: Significantly advancing patient care Recognising innovation 2013-15 Breakthrough Therapy 9 Designations Actemra (Systemic sclerosis) Venetoclax (R/R CLL 17p) YTD 2015 Rank Company # Atezolizumab (NSCLC) 1 Roche 9 ACE 910 (Hemophilia) 2 BMS 8 Esbriet (IPF) 3 Novartis 6 2014 Lucentis (DR) 4 GSK 5 Atezolizumab (Bladder) 4 Merck 5 Alectinib (2L ALK+ NSCLC) 2013 5 JNJ 4 Gazyva (1L CLL) Source: http://www.focr.org/breakthrough-therapies as at 9 September 2015; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non- 9 Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy Pharma: Making a difference for patients Significant opportunities ahead Year Molecule Indication Trial name Event Alectinib ALK+ NSCLC AF-002JG, ACCALIA NME filed 2015 Cotellic+Zelboraf BRAFV600 melanoma coBRIM NME filed Venetoclax 17p del R/R CLL NME filing Atezolizumab 2/3L NSCLC, bladder BIRCH, POPLAR, Imvigor 210 NME filing Ocrelizumab RMS, PPMS OPERA I/II, ORATORIO NME filing 2016 Lebrikizumab Asthma LAVOLTA I/II, ACOUSTICS Pivotal data Perjeta+Herceptin Adjuvant HER2+ breast APHINITY Pivotal data Gazyva Front-line aNHL GOYA Pivotal data ACE 910 Hemophila A Pivotal data Lampalizumab Geographic atrophy CHROMA, SPECTRI Pivotal data 2017 Gazyva 1L iNHL GALLIUM Pivotal data Atezolizumab+chemo 1L NSCLC IMpower 110/150/130/111/131 Pivotal data Oncology Neuroscience Ophthalmology Immunology Timelines may change as trials can be event-driven NME=new molecular entity; NSCLC=non-small cell lung cancer; CLL=chronic lymphoid leukemia; RMS=relapsing multiple sclerosis 10 (MS); PPMS=primary progressive MS; aNHL=aggressive non-hodgkin`s lymphoma; iNHL=indolent non-hodgkin`s lymphoma 2015 outlook: Guidance upgraded Group sales growth1 Mid-single digit Core EPS growth1 Ahead of sales growth2 Dividend outlook Further increase dividend in Swiss francs 1 At constant exchange rates (CER) 11 2 Excluding sale of filgrastim rights in 2014 Pharmaceuticals Division Daniel O’Day COO Roche Pharmaceuticals 12 YTD Sept 2015 sales Innovation Outlook 13 YTD Sept 2015: Pharma sales Strong growth driven by all regions 2015 2014 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 27,690 26,965 3 6 United States 13,047 11,528 13 7 Europe 6,476 7,070 -8 3 Japan 2,341 2,406 -3 8 International 5,826 5,961 -2 6 CER=constant exchange rates 14 YTD Sept 2015: Strong performance from oncology and immunology franchises Herceptin +10% Avastin +9% Perjeta +66% Esbriet n.a. MabThera/Rituxan +5% Kadcyla +57% Actemra/RoActemra +22% Xolair +25% Lucentis -15% US Xeloda -36% Europe Valcyte/Cymevene -47% Japan International Pegasys -48% -500 -250 0 250 500 CHFm Absolute amounts and growth rates at constant exchange rates (CER) 15 YTD Sept 2015: Oncology with +8% growth YoY CER growth Perjeta HER2 Herceptin +19% • Strong uptake of Perjeta and Kadcyla • Growth of Herceptin due to longer treatment Kadcyla • Growth driven by ovarian and cervical Avastin +9% • International: Growth in all regions MabThera/ Rituxan +4% • US: Growth in iNHL maintenance (Oncology) Tarceva -7% • In-class competition Xeloda -36% • Loss of exclusivity • Competitive pressure in US and EU Zelboraf -25% • Cotellic + Zelboraf approval expected in 2015 CHFbn 0 1 2 3 4 5 6 7 CER=constant exchange rates 16 YTD September 2015 Oncology sales: CHF 17.6bn; CER growth +8% HER2 franchise: Growth driven by Herceptin, Perjeta and Kadcyla CHFm YoY CER growth 2,500 HER2 franchise Q3 2015 +16% • Herceptin (+7%): Longer treatment +23% 2,000 duration in combination with Perjeta +15% • Perjeta (+57%): Strong demand in 1L +16% mBC (US & EU) and neoadjuvant (US) 1,500 • Kadcyla (+44%): Growth driven by EU 1,000 Outlook • Perjeta: Neoadjuvant approval in the EU 500 achieved in Q3 ’15 • Kadcyla: Continued growth to be driven 0 by EU and International Q3 12 Q3 13 Q3 14 Q3 15 Herceptin Perjeta Kadcyla CER=constant exchange rates 17 Avastin: Growth in various indications and across all regions CHFm YoY CER growth Avastin Q3 2015 +6% +8% +14% • US (+6%): Continued uptake in lung, 1,600 +11% ovarian and cervical cancer • EU (+5%): Growth in ovarian and cervical 1,200 • International (+16%): Driven by LATAM and China 800 Outlook 400 • Potential filing in mesothelioma • China: Lung cancer indication launched 0 • EU: Avastin + Tarceva filed in lung cancer Q3 12 Q3 13 Q3 14 Q3 15 US Europe International Japan CER=constant exchange rates 18 Immunology: Strong performance by Xolair, Actemra and MabThera/Rituxan CHFm YoY CER growth +23% Xolair (+21%) 1,600 • Allergic asthma and strong growth in +15% +15% chronic idiopathic urticaria due to 1,200 +6% longer treatment duration Actemra (+18%) 800 • SC formulation driving growth • Increasing 1L monotherapy leadership 400 focusing on MTX intolerant patients MabThera/Rituxan (+10%) 0 • Continues to grow in rheumatoid Q3 12 Q3 13 Q3 14 Q3 15 arthritis and vasculitis (GPA and MPA) MabThera/Rituxan (RA) Actemra IV Actemra SC Xolair CellCept Pulmozyme Esbriet Other CER=constant exchange rates; MTX=methotrexate; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis 19 Actemra: Continued uptake in 1L monotherapy SC formulation driving growth in the EU and US CHFm YoY CER growth 400 +18% 350 +28% +20% +27% +23% +21% 32% 300 +33% +23% +23% +33% 250 +30% +32% +27% +32% 200 +46% 150 68% 100 50 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 IV SC CER=constant exchange rates; IV=intravenous formulation; SC=subcutaneous formulation 20 Lucentis: Competitive pressure continues; ophthalmology pipeline progresses Lucentis Q3 2015 Lucentis sales (USDm) • Competitive pressure 500 Outlook • Ongoing competition in AMD & DME 400 • Launch in DR ongoing after first-in- class FDA approval in Q1 2015 Pipeline update ophthalmology 300 • Phase II Port Delivery System study for Lucentis started (expect data 2017) • Anti-VEGF/Ang2 biMab moved into 200 phase II in wAMD Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 • Lampalizumab phase III studies in GA 12 12 13 13 13 13 14 14 14 14 15 15 15 well on track (expect data 2017) wAMD=wet age-related
Load more

Recommended publications
  • Polatuzumab Vedotin - R/R DLBCL RG7769 PD1-TIM3 Bimab - Solid Tumors NSCLC RG7446 Tecentriq – Her2-Pos
    Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development) 1 Changes to the development pipeline FY 2018 update New to phase I New to phase II New to phase III New to registration 3 NMEs: 2 NMEs transitioned from Ph1 1 NME transitioned from Ph2: 2 NMEs + 1 AI transitioned from Ph2 RG6217 - HBV RG7906 - psychiatric disorders RG6042 HTT ASO - Huntington’s following filing in EU and US: RG6237 - neuromuscular disorders RG6058 tiragolumab + Tecentriq - 6 AIs: RG7596 polatuzumab vedotin - r/r DLBCL RG7769 PD1-TIM3 biMAb - solid tumors NSCLC RG7446 Tecentriq – Her2-pos. BC neoadj RG6268 entrectinib - NSCLC ROS1+ 1 AI: 1 NME starting Ph2 RG7446 Tecentriq – high risk NMIBC RG6268 entrectinib – NTRK1 pan-tumor RG7601 Venclexta + gilteritinib – r/r RG6180 iNeST (personalized cancer RG6152 Xofluza - influenza hosp. patients 3 AIs transitioned from Ph3 following AML vaccine) + pembrolizumab - malignant RG6152 Xofluza – influenza pediatric filing in EU and US: melanoma patients RG7446 Tecentriq + nab-paclitaxel 1L 1 NME following termination of Ph3 RG7601 Venclexta - r/r MM t(11:14) non sq NSCLC RG7412 crenezumab – familial RG7601 Venclexta + HMA/LDAC - 1L RG7446 Tecentriq + nab-paclitaxel Alzheimer’s disease healthy individuals AML* 1LTNBC RG7446 Tecentriq + chemo - 1L extensive 1 AI: stage SCLC RG7446 Tecentriq SC – NSCLC Removed from phase I Removed from phase II Removed from phase III Removed from registration 2 NMEs:
    [Show full text]
  • The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients
    biomedicines Review The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients Alessandro Allegra 1,* , Eleonora Di Salvo 2 , Marco Casciaro 3,4, Caterina Musolino 1, Giovanni Pioggia 5 and Sebastiano Gangemi 3,4 1 Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125 Messina, Italy; [email protected] 2 Department of Veterinary Sciences, University of Messina, 98125 Messina, Italy; [email protected] 3 School of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy; [email protected] (M.C.); [email protected] (S.G.) 4 Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy 5 Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-221-2364 Abstract: Although pruritus may sometimes be a consequential situation to neoplasms, it more frequently emerges after commencing chemotherapy. In this review, we present our analysis of the chemotherapy treatments that most often induce skin changes and itching. After discussing conventional chemotherapies capable of inducing pruritus, we present our evaluation of new drugs such as immunological checkpoint inhibitors (ICIs), tyrosine kinase inhibitors, and monoclonal antibodies. Although ICIs and targeted therapy are thought to damage tumor cells, these therapies can modify homeostatic events of the epidermis and dermis, causing the occurrence of cutaneous toxicities in treated subjects. In the face of greater efficacy, greater skin toxicity has been reported for most of these drugs.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • MET Or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib
    www.nature.com/scientificreports OPEN MET or NRAS amplifcation is an acquired resistance mechanism to the third-generation EGFR inhibitor Received: 5 October 2017 Accepted: 16 January 2018 naquotinib Published: xx xx xxxx Kiichiro Ninomiya1, Kadoaki Ohashi1,2, Go Makimoto1, Shuta Tomida3, Hisao Higo1, Hiroe Kayatani1, Takashi Ninomiya1, Toshio Kubo4, Eiki Ichihara2, Katsuyuki Hotta5, Masahiro Tabata4, Yoshinobu Maeda1 & Katsuyuki Kiura2 As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring the EGFR T790M mutation; however, acquired resistance inevitably develops. Therefore, a next-generation treatment strategy is warranted in the osimertinib era. We investigated the mechanism of resistance to a novel EGFR-TKI, naquotinib, with the goal of developing a novel treatment strategy. We established multiple naquotinib-resistant cell lines or osimertinib-resistant cells, two of which were derived from EGFR-TKI-naïve cells; the others were derived from geftinib- or afatinib-resistant cells harboring EGFR T790M. We comprehensively analyzed the RNA kinome sequence, but no universal gene alterations were detected in naquotinib-resistant cells. Neuroblastoma RAS viral oncogene homolog (NRAS) amplifcation was detected in naquotinib-resistant cells derived from geftinib-resistant cells. The combination therapy of MEK inhibitors and naquotinib exhibited a highly benefcial efect in resistant cells with NRAS amplifcation, but the combination of MEK inhibitors and osimertinib had limited efects on naquotinib-resistant cells. Moreover, the combination of MEK inhibitors and naquotinib inhibited the growth of osimertinib-resistant cells, while the combination of MEK inhibitors and osimertinib had little efect on osimertinib-resistant cells.
    [Show full text]
  • Version Introducing VHIO Foreword
    2017SCIENTIFIC REPORT Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Design: Parra estudio Photography: Katherin Wermke Vall d'Hebron Institute of Oncology (VHIO) | 2018 VHIO Scientific Report 2017 Index Scientific Report INTRODUCING VHIO CORE TECHNOLOGIES 02 Foreword 92 Cancer Genomics Group 08 2017: marking the next chapter of 94 Molecular Oncology Group VHIO's translational story 96 Proteomics Group 18 Scientific Productivity: research articles VHIO'S TRANSVERSAL CLINICAL 19 Selection of some of the most relevant TRIALS CORE SERVICES & UNITS articles by VHIO researchers published in 2017 100 Clinical Trials Office 25 A Golden Decade: reflecting on the 102 Research Unit for Molecular Therapy past 10 years of VHIO's translational of Cancer (UITM) – ”la Caixa” success story 104 Clinical Research Oncology Nurses 106 Clinical Research Oncology Pharmacy PRECLINICAL RESEARCH Unit 49 From the Director 50 Experimental Therapeutics Group RECENTLY INCORPORATED GROUPS 52 Growth Factors Group 110 Cellular Plasticity & Cancer Group 54 Mouse Models of Cancer Therapies 112 Experimental Hematology Group Group 114 Tumor Immunology 56 Tumor Biomarkers Group & Immunotherapy Group 116 Applied Genetics of Metastatic Cancer TRANSLATIONAL RESEARCH Group 61 From the Director 118 Chromatin Dynamics in Cancer Group 62 Gene Expression & Cancer Group 120 Prostate Cancer Translational Research Group 64 Stem Cells & Cancer Group 122 Radiomics Group CLINICAL
    [Show full text]
  • Roche/Genentech Managed RG7986 ADC R/R NHL CHU Chugai Managed IONIS IONIS Managed 74 Status As of January 28, 2016 PRO Proximagen Managed
    Roche 2015 results London, 28 January 2016 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • The Role of Single Arm Trials in Oncology Drug Development EMA-ESMO Workshop on Single-Arm Trials for Cancer Drug Market Access 30Th June 2016
    The role of Single Arm Trials in Oncology Drug Development EMA-ESMO Workshop on single-arm trials for cancer drug market access 30th June 2016 Gideon Blumenthal, MD Office of Hematology and Oncology Products U.S. Food and Drug Administration Challenges with “newparadigm” with Challenges Challenges ROS1 MET PTEN+ PTEN+ Targeted KRAS Therapy N=50 p53 with “oldparadigm” - 200 LKB1 ??? ORR Magnitude, Durable Large EGFR ALK N=800 R - 1200 1. Feasibility of screening/enrolling pts for RCT? for pts screening/enrolling of Feasibility 1. 2. Equipoise Lost? Equipoise 2. Platinum doublet Platinum Platinum doublet Platinum + drug X EFFECT CLINICALLY DETECTION “FAILURE” HIGHRISK 30 ) % ( 25 s n Patients with TARGET Gene events by category (%) o i t 0 25 50 75 100 a r 20 e All t l a Common (5% or greater) e 15 Intermediate (2−5%) n e g Rare (Less than 2%) T 10 2 E G R A 5 T 0 3 1 3 4 5 1 2 4 L 2 1 2 2 3 3 1 1 7 1 1 2 1 2 2 1 1 4 1 1 3 1 1 4 4 2 2 6 1 6 2 1 1 1 4 1 L 4 2 2 2 1 1 2 1 1 1 3 1 3 1 1 3 3 1 2 2 2 2 1 L 2 4 5 L 1 1 1 1 2 3 6 F T T T F F A A S P S A B S K K A B B A S A A A A R N C R R R C R R G O Q M I I 5 L L L 1 L 1 L − F T T T T F F T T P 2 A B A S A A K B B B K 1 K A B X L K V 2 K K P 3 V K E K T S V V P B K 1 A H H R H E H R E D H D R 1 H H C R N D D D R R R H H D D H C H D A OR F T A B A A Y O A K C E P R Y R A M M R A T D W O R I K M L B 2 P X K 2 B 2 2 A 3 C K T E T T L A T T C K K A B N Z F F F F N B B A B A A A S 3 N H H C M C R R N N A C N D S S S E N R A S S N S V C D N A R T C C F D R D C R F N N D R N D R R B O S P R A R N R A
    [Show full text]
  • 2017 Immuno-Oncology Medicines in Development
    2017 Immuno-Oncology Medicines in Development Adoptive Cell Therapies Drug Name Organization Indication Development Phase ACTR087 + rituximab Unum Therapeutics B-cell lymphoma Phase I (antibody-coupled T-cell receptor Cambridge, MA www.unumrx.com immunotherapy + rituximab) AFP TCR Adaptimmune liver Phase I (T-cell receptor cell therapy) Philadelphia, PA www.adaptimmune.com anti-BCMA CAR-T cell therapy Juno Therapeutics multiple myeloma Phase I Seattle, WA www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 "armored" CAR-T Juno Therapeutics recurrent/relapsed chronic Phase I cell therapy Seattle, WA lymphocytic leukemia (CLL) www.junotherapeutics.com Memorial Sloan Kettering New York, NY anti-CD19 CAR-T cell therapy Intrexon B-cell malignancies Phase I Germantown, MD www.dna.com ZIOPHARM Oncology www.ziopharm.com Boston, MA anti-CD19 CAR-T cell therapy Kite Pharma hematological malignancies Phase I (second generation) Santa Monica, CA www.kitepharma.com National Cancer Institute Bethesda, MD Medicines in Development: Immuno-Oncology 1 Adoptive Cell Therapies Drug Name Organization Indication Development Phase anti-CEA CAR-T therapy Sorrento Therapeutics liver metastases Phase I San Diego, CA www.sorrentotherapeutics.com TNK Therapeutics San Diego, CA anti-PSMA CAR-T cell therapy TNK Therapeutics cancer Phase I San Diego, CA www.sorrentotherapeutics.com Sorrento Therapeutics San Diego, CA ATA520 Atara Biotherapeutics multiple myeloma, Phase I (WT1-specific T lymphocyte South San Francisco, CA plasma cell leukemia www.atarabio.com
    [Show full text]
  • Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
    cells Review Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses Clément Anfray 1, Aldo Ummarino 2 , Fernando Torres Andón 1,3 and Paola Allavena 1,* 1 IRCCS Istituto Clinico Humanitas, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy; [email protected] (C.A.); [email protected] (F.T.A.) 2 Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy; [email protected] 3 Center for Research in Molecular Medicine & Chronic Diseases (CIMUS), Universidade, de Santiago de Compostela, Campus Vida, 15706 Santiago de Compostela, Spain * Correspondence: [email protected] Received: 4 December 2019; Accepted: 20 December 2019; Published: 23 December 2019 Abstract: Established evidence demonstrates that tumor-infiltrating myeloid cells promote rather than stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at tumor sites, and here they support cancer proliferation and distant spreading, as well as contribute to an immune-suppressive milieu. Their pro-tumor activities hamper the response of cancer patients to conventional therapies, such as chemotherapy or radiotherapy, and also to immunotherapies based on checkpoint inhibition. Active research frontlines of the last years have investigated novel therapeutic strategies aimed at depleting TAMs and/or at reprogramming their tumor-promoting effects, with the goal of re-establishing a favorable immunological anti-tumor response within the tumor tissue. In recent years, numerous clinical trials have included pharmacological strategies to target TAMs alone or in combination with other therapies. This review summarizes the past and current knowledge available on experimental tumor models and human clinical studies targeting TAMs for cancer treatment.
    [Show full text]
  • Trastuzumab and Paclitaxel in Patients with EGFR Mutated NSCLC That Express HER2 After Progression on EGFR TKI Treatment
    www.nature.com/bjc ARTICLE Clinical Study Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment Adrianus J. de Langen1,2, M. Jebbink1, Sayed M. S. Hashemi2, Justine L. Kuiper2, J. de Bruin-Visser2, Kim Monkhorst3, Erik Thunnissen4 and Egbert F. Smit1,2 BACKGROUND: HER2 expression and amplification are observed in ~15% of tumour biopsies from patients with a sensitising EGFR mutation who develop EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumour responses. METHODS: A single arm phase II study was performed to study the safety and efficacy of trastuzumab and paclitaxel treatment in patients with a sensitising EGFR mutation who show HER2 expression in a tumour biopsy (IHC ≥ 1) after progression on EGFR TKI treatment. Trastuzumab (first dose 4 mg/kg, thereafter 2 mg/kg) and paclitaxel (60 mg/m2) were dosed weekly until disease progression or unacceptable toxicity. The primary end-point was tumour response rate according to RECIST v1.1. RESULTS: Twenty-four patients were enrolled. Nine patients were exon 21 L858R positive and fifteen exon 19 del positive. Median HER2 IHC was 2+ (range 1–3). For 21 patients, gene copy number by in situ hybridisation could be calculated: 5 copies/nucleus (n = 9), 5–10 copies (n = 8), and >10 copies (n = 4). An objective response was observed in 11/24 (46%) patients. Highest response rates were seen for patients with 3+ HER2 IHC (12 patients, ORR 67%) or HER2 copy number ≥10 (4 patients, ORR 100%). Median tumour change in size was 42% decrease (range −100% to +53%).
    [Show full text]